Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection

Cecile L. Tremblay; Jennifer L. Hicks; Lorraine Sutton; Francoise Giguel; Theresa Flynn; Mary Johnston; Paul E. Sax; Bruce D. Walker; Martin S. Hirsch; Eric S. Rosenberg; Richard T. D'Aquila

doi:10.1097/00002030-200305020-00021

Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection

Cecile L. Tremblay^*, Jennifer L. Hicks, Lorraine Sutton, Francoise Giguel, Theresa Flynn, Mary Johnston, Paul E. Sax, Bruce D. Walker, Martin S. Hirsch, Eric S. Rosenberg, Richard T. D'Aquila

^*Corresponding author for this work

Medicine, Infectious Diseases Division

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

We studied 14 patients acutely infected with wild-type HIV, who underwent supervised treatment interruptions after initial antiretroviral treatment including lamivudine. Lamivudine resistance mutations emerged for the first time during supervised treatment interruptions in one patient. Resistance should be monitored in supervised treatment interruptions trials, because mutations may first be detected only after therapy is interrupted.

Original language	English (US)
Pages (from-to)	1086-1089
Number of pages	4
Journal	AIDS
Volume	17
Issue number	7
DOIs	https://doi.org/10.1097/00002030-200305020-00021
State	Published - May 2 2003

ASJC Scopus subject areas

Infectious Diseases
Immunology and Allergy
Immunology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/00002030-200305020-00021

Cite this

@article{d4bda0d5663844dfb3193570204f6980,

title = "Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection",

abstract = "We studied 14 patients acutely infected with wild-type HIV, who underwent supervised treatment interruptions after initial antiretroviral treatment including lamivudine. Lamivudine resistance mutations emerged for the first time during supervised treatment interruptions in one patient. Resistance should be monitored in supervised treatment interruptions trials, because mutations may first be detected only after therapy is interrupted.",

author = "Tremblay, {Cecile L.} and Hicks, {Jennifer L.} and Lorraine Sutton and Francoise Giguel and Theresa Flynn and Mary Johnston and Sax, {Paul E.} and Walker, {Bruce D.} and Hirsch, {Martin S.} and Rosenberg, {Eric S.} and D'Aquila, {Richard T.}",

year = "2003",

month = may,

day = "2",

doi = "10.1097/00002030-200305020-00021",

language = "English (US)",

volume = "17",

pages = "1086--1089",

journal = "AIDS",

issn = "0269-9370",

publisher = "Lippincott Williams and Wilkins",

number = "7",

}

TY - JOUR

T1 - Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection

AU - Tremblay, Cecile L.

AU - Hicks, Jennifer L.

AU - Sutton, Lorraine

AU - Giguel, Francoise

AU - Flynn, Theresa

AU - Johnston, Mary

AU - Sax, Paul E.

AU - Walker, Bruce D.

AU - Hirsch, Martin S.

AU - Rosenberg, Eric S.

AU - D'Aquila, Richard T.

PY - 2003/5/2

Y1 - 2003/5/2

N2 - We studied 14 patients acutely infected with wild-type HIV, who underwent supervised treatment interruptions after initial antiretroviral treatment including lamivudine. Lamivudine resistance mutations emerged for the first time during supervised treatment interruptions in one patient. Resistance should be monitored in supervised treatment interruptions trials, because mutations may first be detected only after therapy is interrupted.

AB - We studied 14 patients acutely infected with wild-type HIV, who underwent supervised treatment interruptions after initial antiretroviral treatment including lamivudine. Lamivudine resistance mutations emerged for the first time during supervised treatment interruptions in one patient. Resistance should be monitored in supervised treatment interruptions trials, because mutations may first be detected only after therapy is interrupted.

UR - http://www.scopus.com/inward/record.url?scp=0038326543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038326543&partnerID=8YFLogxK

U2 - 10.1097/00002030-200305020-00021

DO - 10.1097/00002030-200305020-00021

M3 - Article

C2 - 12700462

AN - SCOPUS:0038326543

SN - 0269-9370

VL - 17

SP - 1086

EP - 1089

JO - AIDS

JF - AIDS

IS - 7

ER -

Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this